Telmisartan in the treatment of hypertension.
BACKGROUND
Telmisartan is an orally active angiotensin II receptor antagonist prescribed once daily.


OBJECTIVE
To evaluate the efficacy of telmisartan on blood pressure control, and on other end points, when given as monotherapy or in combination.


METHODS
Review of published literature.


RESULTS
Telmisartan produces more effective control of blood pressure over 24 h, especially in the last 6 h of the dosing interval, compared with other antihypertensive agents. It also possesses pleiotrophic effects on lipid and glucose metabolism, but lacks evidence of efficacy in reducing vascular events.


CONCLUSIONS
Clinical outcome trials expected to report in 2008 will provide hard end points that may demonstrate advantages of telmisartan as monotherapy, or in combination with angiotensin-converting enzyme inhibitors, for managing hypertension.
Rosario
Barbara H
BH
Sheffield Teaching Hospitals NHS Foundation Trust, Department of Geriatric Medicine, Sir Robert Hadfield Wing, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.
Hendra
Timothy James
TJ
D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001565:Benzoates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D050260:Carbohydrate Metabolism / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D050356:Lipid Metabolism / Q000187:drug effects; D000077333:Telmisartan; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D000077333:Telmisartan